id588674411
Between 2012 and 2021, drug companies spent substantially more on stock buybacks and dividends to reward shareholders than they did on research and development.
✏️ Keep in mind that, whenever they say they want to do the right thing for patients, their money habits speak a whole different game.
Link to original
🔗 View Highlight